NEW YORK (GenomeWeb news) – Cepheid has launched its molecular diagnostic test for Clostridium difficile as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices.
 
The PCR-based test runs on the company’s GeneXpert System, and it detects and identifies common strains of the C. difficile infection, including the virulent Type 027 strain that had been reported in 16 European countries through June.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.